Shares of Zydus Lifesciences touched 52-week high of Rs 1,203.20 in the early trade on July 11, riding on the final approval from the United States Food and Drug Administration (USFDA) to market a key drug used to treat chronic heart failure.
At 09:21am, Zydus Lifesciences was quoting at Rs 1,178.95, down Rs 1.45, or 0.12 percent, on the BSE.
Sacubitril and Valsartan Tablets (24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg) are combinations used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization.
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
The group now has 399 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.
Catch all market action in our live blogAlso, company received tentative approval from the USFDA to market Diroximel Fumarate Delayed-Release Capsules, 231 mg.
Earlier in this month, company received tentative approval from the USFDA to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
